3.29
Prodrogas
Las prodrogas son una clase de compuestos farmacéuticos que sufren un proceso de biotransformación dentro del cuerpo para convertirse en un fármaco fa…
Los profármacos son precursores inactivos de fármacos que se convierten enzimática o químicamente en fármacos activos dentro del organismo. Se metabolizan principalmente en el hígado o en el sitio de acción.
En comparación con el fármaco activo, la mayoría de los profármacos tienen una mejor absorción, una mejor estabilidad química, una mayor permeabilidad de la membrana, un sabor desagradable y menos efectos adversos.
Por lo general, los profármacos contienen un fármaco activo unido covalentemente a un grupo químico llamado portador. Cuando un profármaco ligado a un portador entra en el cuerpo, las enzimas metabolizan el portador adjunto, liberando el fármaco activo.
Por ejemplo, el enalapril, un fármaco antihipertensivo, es metabolizado por la esterasa hepática, produciendo enalaprilat. De lo contrario, este ácido dicarboxílico activo requiere administración intravenosa.
Por el contrario, un profármaco bioprecursor es una forma químicamente inerte de un fármaco sin portador que se transforma enzimáticamente en un fármaco activo en el organismo.
La levodopa, un bioprecursor de la dopamina, también es un aminoácido. Utiliza transportadores de aminoácidos para cruzar la barrera hematoencefálica, donde las descarboxilasas escinden su grupo carboxilo para liberar el neurotransmisor.
View the full transcript and gain access to JoVE Core videos
Q1: What is a prodrug and how does it differ from an active drug?
A prodrug is an inactive drug precursor that undergoes enzymatic or chemical conversion into an active drug within the body. Unlike active drugs, prodrugs offer improved absorption, better chemical stability, enhanced membrane permeability, reduced adverse effects, and no foul taste. This chemical modification allows prodrugs to overcome limitations of the parent drug, such as poor solubility or unfavorable pharmacokinetic properties.
Q2: How do carrier-linked prodrugs work in the body?
Carrier-linked prodrugs contain an active drug covalently bonded to a chemical carrier group. When the prodrug enters the body, enzymes metabolize the attached carrier, releasing the active drug. For example, enalapril is metabolized by liver esterase to produce enalaprilat, an active dicarboxylic acid that would otherwise require intravenous administration, making oral delivery possible.
Q3: What are bioprecursor prodrugs and how do they activate?
Bioprecursor prodrugs are chemically inert drug forms without a carrier that transform enzymatically into active drugs in the body. Levodopa exemplifies this type: as an amino acid, it uses drug absorption mechanism carrier mediated membrane transport to cross the blood-brain barrier, where decarboxylases cleave its carboxyl group to release dopamine, the active neurotransmitter.
Q4: Where do prodrugs undergo metabolic conversion in the body?
Prodrugs are primarily metabolized in the liver through enzymatic processes such as hydrolysis, oxidation, or reduction. However, some prodrugs are metabolized at their site of action, while others undergo transformation extracellularly in blood or gastrointestinal fluids. This site-specific activation allows prodrugs to target particular tissues or cells, minimizing off-target effects.
Q5: What advantages do prodrugs offer in drug development and patient care?
Prodrugs extend drug life and enhance patient compliance by offering alternative administration routes or reducing dosing frequency. They improve drug efficacy and safety while providing patient convenience. By utilizing site-specific enzymes or transporters, prodrugs can target particular tissues, minimizing unwanted effects and improving therapeutic outcomes compared to the parent drug.
Q6: How do prodrugs improve the absorption and stability of drugs?
Prodrugs enhance absorption and chemical stability by modifying the drug's chemical structure to improve its ADME characteristics—absorption, distribution, metabolism, and elimination. This modification increases membrane permeability and solubility, allowing drugs that are poorly absorbed or unstable in their active form to be administered orally or through alternative routes with better bioavailability.
Q7: Why might a drug require conversion to a prodrug form for oral administration?
Some active drugs cannot be given orally due to poor absorption, chemical instability, or inability to cross physiological barriers. Converting them to prodrugs with improved membrane permeability and stability allows oral administration. Enalapril demonstrates this: the active enalaprilat cannot be orally absorbed, so the prodrug form enables effective oral delivery while maintaining therapeutic efficacy.